CTMX vs EEX Comparison

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Emerald Holding Inc is a business-to-business (B2B) event organizer principally in the United States, with operations in the United Kingdom (U.K.), France, and other markets. The company is engaged in three complementary business lines: Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry; the Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division provides B2B e-commerce and digital merchandising solutions to manufacturers and retailers. Emerald's key revenue is derived from the Connections business, its only reportable segment.